IP Library Granted Patent US 11,110,126
Granted Patent B2
US 11,110,126 · App. 16/281,372 · Granted Sep 7, 2021

Method of expanding NK cell and composition for culturing

Inventors: Kyung-Mi Lee (Seoul, KR); Jeongwon Sohn (Seoul, KR); Seon Ah Lim (Seoul, KR); Jang-Mi Lim (Pohang-Si, KR)
Assignee: Korea University Research and Business Foundation
A61K35/17C12N5/0646A61K2039/5158A61K2039/585C12N2501/998C12N2501/999
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,110,126
App. No.
16/281,372
Granted
Sep 7, 2021
Kind
B2
Abstract

Provided are a method of ex-vivo culture of natural killer (NK) cells by treating the cells with a reactive oxygen species (ROS) inhibitor and/or a p53 protein inhibitor; and a composition comprising the cultured NK cells. By reducing the activity of ROS and p53 proteins during ex-vivo culture, NK cells may have achieved greater expansion efficiency without altering their anti-tumor cytotoxicity.

Claims (7)

1. A method of enhancing NK cell expansion, comprising:

treating natural killer (NK) cells with a p53 inhibitor; or a reactive oxygen species (ROS) inhibitor and a p53 inhibitor, wherein the p53 inhibitor is one or more selected from the group consisting of 2-(2-imino-4,5,6,7-tetrahydrobenzothiazol-3-yl)-1-p-tolylethanone hydrobromide (pifithrin-α) and pifithrin-μ.

2. The method of claim 1 , wherein NK cells are derived from human peripheral blood mononuclear cells (PBMCs).

3. The method of claim 1 , wherein the ROS inhibitor is one or more selected from the group consisting of 1-(4-hydroxy-3-methoxyphenyl)-ethanone (apocynin), 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (trolox), pyrrolidine dithiocarbamate (PDTC), glutathione (GSH), catalase, manganese superoxide dismutase (MnSOD), vitamin E, and Quercetin.

4. The method of claim 1 , wherein the inhibitors include trolox and pifithrin-α in a molar ratio of 50 to 150:1.

5. The method of claim 1 , wherein the treatment includes culturing NK cells expanded from PBMCs for 1 to 3 weeks in the presence of the p53 inhibitor; or the ROS inhibitor and the p53 inhibitor.

6. The method of claim 1 , wherein the method comprises: inducing and expanding NK cells from PBMCs; and culturing the expanded NK cells for 1 to 3 weeks in the presence of the p53 inhibitor; or the ROS inhibitor and the p53 inhibitor.

Priority Claims (2)
KR 10-2015-0098269 · Jul 10, 2015 · national
KR 10-2016-0085642 · Jul 6, 2016 · national
Continuity (2)
Division 15204407 · Jul 7, 2016
Related Publication 20190183995A1 · Jun 20, 2019
Cited By (1)
US 12,674,138